Acute Liver Failure Market Share

North American Market Forecast

North America acute liver failure market is expected to hold a share of 37% during the forecast period. The growth can be attributed to an unhealthy lifestyle that causes obesity and weight gain, the presence of key players, and rising healthcare costs in the region. Furthermore, the region has a well-developed healthcare infrastructure, including specialized liver transplant centers, advanced diagnostic capabilities, and access to innovative treatments and therapies. For instance, to assist the biotech company in navigating a novel and potentially challenging launch in nonalcoholic steatohepatitis (NASH), Madrigal Pharmaceuticals has appointed Carole Huntsman as its new chief commercial officer.

APAC Market Statistics

Acute liver failure market in Asia Pacific is anticipated to hold a share of 27% during the forecast period. Governments in the region are implementing public health programs and initiatives to address liver diseases, including hepatitis B, screening programs for liver cancer, and awareness campaigns to promote healthy lifestyles and reduce alcohol consumption. As per a report, around 44% of deaths are caused by liver cancer in Asia Pacific. Also, the region is experiencing a rising incidence of liver diseases and hepatitis B and C, which is accelerating the acute liver failure market growth.